Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | Optimizing haplo-SCT for the treatment of AML

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses advancements in haploidentical stem cell transplantation (haplo-SCT) for the treatment of acute myeloid leukemia (AML). He discusses the use of post-transplant cyclophosphamide (PTCy) to mitigate graft-versus-host disease (GvHD), with the potential addition of anti-thymocyte globulin (ATG). He also points out the benefits of using non-myeloablative conditioning, especially for older patients. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.